A chemically diverse range of novel tetraoxanes was synthesized and evaluated in vitro against intramacrophage amastigote forms of Leishmania donovani. All 15 tested tetraoxanes displayed activity, with IC50 values ranging from 2 to 45 µm. The most active tetraoxane, compound LC140, exhibited an IC50 value of 2.52 ± 0.65 µm on L. donovani intramacrophage amastigotes, with a selectivity index of 13.5. This compound reduced the liver parasite burden of L. donovani-infected mice by 37% after an intraperitoneal treatment at 10 mg/kg/day for five consecutive days, whereas miltefosine, an antileishmanial drug in use, reduced it by 66%. These results provide a relevant basis for the development of further tetraoxanes as effective, safe, and cheap drugs against leishmaniasis.
一系列新型四氧杂环己烷类化合物在体外对利什曼原虫(Leishmania donovani)巨噬细胞内阿马斯蒂果形态进行了合成和评价。所有15种测试的四氧杂环己烷类化合物均显示出活性,IC50值范围为2至45 µm。其中最活性的四氧杂环己烷类化合物LC140,在L. donovani巨噬细胞内阿马斯蒂果上表现出IC50值为2.52 ± 0.65 µm,选择性指数为13.5。该化合物通过腹腔注射每天10 mg/kg,连续五天治疗后,将感染利什曼原虫的小鼠肝脏寄生虫负担减少了37%,而目前使用的抗利什曼病药物米尔托芬辛则将其减少了66%。这些结果为进一步开发四氧杂环己烷类化合物作为有效、安全和廉价的利什曼病药物提供了重要依据。